Rogentine C N, Dellon A L, Chretien P B
Cancer. 1977 Jun;39(6):2345-7. doi: 10.1002/1097-0142(197706)39:6<2345::aid-cncr2820390605>3.0.co;2-w.
Seventy patients with squamous carcinoma or adenocarcinoma of the lung were HLA typed at the time of their diagnosis and initial therapy. No abnormal HLA antigen frequencies were found. However, the possession of HLA-Aw19 or HLA-B5 was significantly correlated with two year disease-free survival. Twelve of 21 patients (57%) with either Aw 19 or B5 were disease-free at two years. In contrast, only six of 48 patients (13%) not having either antigen were disease-free (p less than .001). One patient was lost to follow-up. It is possible that Aw 19 and/or B5 confer resistance to progression of bronchogenic carcinoma on their possessors.
70例肺鳞癌或腺癌患者在诊断及初始治疗时进行了HLA分型。未发现异常的HLA抗原频率。然而，拥有HLA-Aw19或HLA-B5与两年无病生存率显著相关。21例拥有Aw19或B5的患者中有12例（57%）两年无病。相比之下，48例不具备这两种抗原的患者中只有6例（13%）无病（p小于0.001）。有1例患者失访。有可能Aw19和/或B5使携带者对支气管源性癌的进展产生抗性。
